Humacyte Gestione

Gestione criteri di controllo 3/4

Humacyte Il CEO è Laura Niklason, nominato in Jan2004, e ha un mandato di 20.83 anni. la retribuzione annua totale è $ 2.63M, composta da 23% di stipendio e 77% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.19% delle azioni della società, per un valore di $ 1.07M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.3 anni e 3.3 anni.

Informazioni chiave

Laura Niklason

Amministratore delegato

US$2.6m

Compenso totale

Percentuale dello stipendio del CEO	23.0%
Mandato del CEO	20.8yrs
Proprietà del CEO	0.2%
Durata media del management	3.3yrs
Durata media del Consiglio di amministrazione	3.3yrs

Aggiornamenti recenti sulla gestione

Shareholders Will Probably Not Have Any Issues With Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation

Jun 05

Recent updates

Shareholders Will Probably Not Have Any Issues With Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation

Jun 05

Humacyte: A Strong Opportunity In Wound Healing - A 'Buy' Before Price Gets Too High

May 14

Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?

Feb 14

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Laura Niklason rispetto agli utili di Humacyte?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	-US$153m
Jun 30 2024	n/a	n/a	-US$140m
Mar 31 2024	n/a	n/a	-US$106m
Dec 31 2023	US$3m	US$604k	-US$111m
Sep 30 2023	n/a	n/a	-US$89m
Jun 30 2023	n/a	n/a	-US$89m
Mar 31 2023	n/a	n/a	-US$29m
Dec 31 2022	US$2m	US$500k	-US$12m
Sep 30 2022	n/a	n/a	US$34m
Jun 30 2022	n/a	n/a	US$28m
Mar 31 2022	n/a	n/a	-US$26m
Dec 31 2021	US$11m	US$500k	-US$26m
Sep 30 2021	n/a	n/a	-US$85m
Jun 30 2021	n/a	n/a	-US$71m
Mar 31 2021	n/a	n/a	-US$69m
Dec 31 2020	US$619k	US$75k	-US$67m

Compensazione vs Mercato: La retribuzione totale di Laura ($USD 2.63M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 2.24M ).

Compensazione vs guadagni: La retribuzione di Laura è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Laura Niklason (61 yo)

20.8yrs

Mandato

US$2,625,702

Compensazione

Dr. Laura E. Niklason, M.D., Ph D., serves as President and Chief Executive Officer at Humacyte, Inc. since November 2020. She founded Humacyte, Inc. in 2004 and served as its Chief Scientist from 2005 to...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Laura Niklason	Founder	20.8yrs	US$2.63m	0.19% $ 1.1m
Dale Sander	CFO, Chief Corporate Development Officer & Treasurer	4yrs	US$1.35m	0.018% $ 99.0k
Heather Prichard	Chief Operating Officer	5.5yrs	US$1.27m	Nessun dato
Sabrina Osborne	Chief People Officer	no data	Nessun dato	Nessun dato
William Scheessele	Chief Commercial Officer	3.3yrs	Nessun dato	Nessun dato
Shamik Parikh	Chief Medical Officer	2.6yrs	US$1.53m	0% $ 0
Harold Alterson	Chief Quality Officer	2.3yrs	Nessun dato	Nessun dato
Yang Cao	Chief Regulatory Officer	2.2yrs	Nessun dato	Nessun dato

3.3yrs

Durata media

55yo

Età media

Gestione esperta: Il team dirigenziale di HUMA è considerato esperto (durata media dell'incarico 3.3 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Laura Niklason	Founder	20.8yrs	US$2.63m	0.19% $ 1.1m
Max Wallace	Independent Director	19.4yrs	US$76.76k	0.050% $ 282.7k
Brady Dougan	Director	19.8yrs	US$71.76k	0.40% $ 2.2m
Susan Windham-Bannister	Independent Director	3.3yrs	US$71.76k	0% $ 0
Todd Pope	Independent Director	no data	US$76.76k	0% $ 0
Kathleen Sebelius	Independent Chairman of the Board	9.2yrs	US$96.76k	0.032% $ 180.5k
Michael Constantino	Independent Director	no data	US$79.26k	0.0096% $ 54.1k
Diane Seimetz	Independent Director	2.4yrs	US$71.76k	0% $ 0
Emery Brown	Independent Director	3.3yrs	US$71.76k	0% $ 0
C. Green	Independent Director	2.2yrs	US$71.76k	0% $ 0
John Bamforth	Director	less than a year	Nessun dato	Nessun dato
Keith Jones	Director	less than a year	Nessun dato	Nessun dato

3.3yrs

Durata media

64.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di HUMA sono considerati esperti (durata media dell'incarico 3.3 anni).

Humacyte Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Key Executive notifies of intention to sell stock

Humacyte Announces the Addition of John P. Bamforth and Keith Anthony Jones to the Company’s Board of Directors

High number of new directors

Independent Chairman of the Board exercised options to buy US$234k worth of stock.

Shareholders Will Probably Not Have Any Issues With Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation

Chief Operating Officer recently sold US$502k worth of stock

Recent updates

Humacyte, Inc. Announces Clinical Results Highlighting Benefit of the ATEV™ in the Repair of Civilian and Military Arterial Injury Published in Jama Surgery

Holzer & Holzer, LLC Files Class Action Lawsuit Against Humacyte, Inc

Humacyte, Inc. Presents Preclinical Results of Small-Diameter ATEV™? for Coronary Artery Bypass Grafting at American Heart Association's Scientific Sessions 2024

Consensus revenue estimates fall by 32%

Humacyte, Inc. has filed a Follow-on Equity Offering.

New minor risk - Profitability

Forecast to breakeven in 2026

Humacyte, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Humacyte Announces Presentation of Positive Results from V007 Phase 3 Av Access Clinical Trial At the American Society of Nephrology’S Kidney Week 2024

Humacyte, Inc. has filed a Follow-on Equity Offering in the amount of $30.00001 million.

Humacyte, Inc. has filed a Follow-on Equity Offering in the amount of $30.00001 million.

Humacyte, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Humacyte, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Humacyte: Navigating The FDA Uncertainty And ATEV's Potential

Humacyte, Inc. Announces Allowance of U.S. Patent Covering BioVascular Pancreas

Price target increased by 20% to US$13.17

Key Executive notifies of intention to sell stock

Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?

New minor risk - Insider selling

Humacyte, Inc. Acellular Tissue Engineered Vessel Meets Primary Endpoints in V007 Phase 3 Clinical Trial in Arteriovenous Access for Hemodialysis

Humacyte: Pioneering Vascular Solutions With High-Stakes Potential

Price target increased by 13% to US$9.30

Consensus revenue estimates increase by 13%

Humacyte Announces the Addition of John P. Bamforth and Keith Anthony Jones to the Company’s Board of Directors

High number of new directors

Humacyte, Inc.(NasdaqGS:HUMA) dropped from Russell Small Cap Comp Value Index

Humacyte, Inc. Presents Positive Preclinical Data for Its Biovascular Pancreas (Bvp™?) Program

Independent Chairman of the Board exercised options to buy US$234k worth of stock.

Shareholders Will Probably Not Have Any Issues With Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation

Chief Operating Officer recently sold US$502k worth of stock

Chief Operating Officer notifies of intention to sell stock

Independent Director recently bought US$668k worth of stock

Humacyte: A Strong Opportunity In Wound Healing - A 'Buy' Before Price Gets Too High

Humacyte, Inc. to Report Q1, 2024 Results on May 10, 2024

Humacyte, Inc., Annual General Meeting, Jun 11, 2024

Consensus revenue estimates decrease by 12%, EPS upgraded

Price target increased by 7.1% to US$7.50

New major risk - Revenue and earnings growth

Humacyte, Inc. to Report Q4, 2023 Results on Mar 22, 2024

Humacyte, Inc. has completed a Follow-on Equity Offering in the amount of $40.2 million.

New minor risk - Shareholder dilution

Humacyte, Inc. has completed a Follow-on Equity Offering in the amount of $40.2 million.

Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?

Humacyte, Inc. Announces U.S. Food and Drug Administration Accepts and Grants Priority Review to Humacyte's Biologics License Application

New minor risk - Share price stability

Consensus revenue estimates decrease by 12%

Humacyte, Inc. Submits Biologics License Application to U.S. Food and Drug Administration Seeking Approval of Human Acellular Vessel (Hav) for the Treatment of Vascular Trauma

Humacyte, Inc. Announces Presentations of Positive Clinical Results of the Human Acellular Vessel™? (HAV™?) in the Treatment of Vascular Trauma

Humacyte, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Humacyte, Inc. Publishes Preclinical Results Showing Human Acellular Vessel™? Patency as Modified Blalock-Taussig-Thomas Shunt in Juvenile Primate Model

Founder exercised options to buy US$280k worth of stock.

Humacyte, Inc. Announces Positive Top Line Results from Phase 2/3 Trial of Human Acellular Vessel™? (HAV™?) in Treatment of Patients with Vascular Trauma

Humacyte, Inc. Announces the Presentation of Results from FDA Regulated, Investigator-Sponsored Clinical Study Conducted At the Mayo Clinic

Consensus revenue estimates fall by 33%

Humacyte, Inc. Presents Clinical Performance of Human Acellular Vessel (HAV) from Ukrainian Humanitarian Program

New major risk - Revenue size

First half 2023 earnings released: US$0.58 loss per share (vs US$0.17 profit in 1H 2022)

Humacyte, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Humacyte, Inc. Announces Publication of Biological Mechanism Explaining Low Rates of Infection Observed in Clinical Study of Human Acellular Vessel

Humacyte, Inc. Completes Enrollment in Phase 2/3 Trial of Human Acellular Vessel(Tm) (Hav(Tm)) for Vascular Trauma Repair

Chief Operating Officer exercised options to buy US$240k worth of stock.

First quarter 2023 earnings released: US$0.36 loss per share (vs US$0.19 loss in 1Q 2022)

Humacyte, Inc. to Report Q1, 2023 Results on May 12, 2023

Price target decreased by 24% to US$7.35

Consensus revenue estimates decrease by 45%, EPS upgraded

Price target decreased by 15% to US$9.46

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment deteriorates as stock falls 16%

Founder exercised options to buy US$321k worth of stock.